Kun Liu
6PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jan 01, 2026
International Cost-Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced-Stage Classic Hodgkin's Lymphoma.Youwen Zhu, Kun Liu, Steven T Rosen
|Jul 07, 2025
International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer.Kun Liu, Youwen Zhu, Hong Zhu
|Jan 08, 2025
Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis.Youwen Zhu, Kun Liu, Hong Zhu
|Jun 10, 2024
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.Youwen Zhu, Kun Liu, Hong Zhu
|Apr 05, 2024
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis.Youwen Zhu, Yinxin Lin, Kun Liu
|Jul 21, 2023
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.Youwen Zhu, Qiuping Yang, Kun Liu
Pageof 1
